Latest News

Novel HIV inhibitors safe, well-tolerated

SEATTLE — Researchers presented positive findings from early-stage clinical trials of two novel HIV inhibitors at CROI.
At a news conference, Jennifer E. Sager, PhD, a clinical pharmacologist at Gilead Sciences, presented results of a phase 1 study on the safety, tolerability and pharmacokinetics of GS-6207, a first-in-class HIV capsid inhibitor, for use as a long-acting antiretroviral agent.
In the ongoing randomized, blinded, placebo-controlled trial, 40 healthy volunteers were randomly assigned to receive placebo (n = 8) or a single shot of GS-6207 (n = 32) at 30 mg, 100 mg, 300 mg or

Source link

Related posts

GP Required – Dublin


Antibiotics still routinely prescribed in the ER for infants with viral lung infections


At Clínica Amiga, language barriers come down for Hispanic pediatric patients


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy